Ronald E. Savage

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

Timothy A. Yap, David Olmos, André T. Brunetto et al. · Journal of Clinical Oncology · 2011 · 193 citations · Full text

Amyloid-β ¹¹ C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials

Enchi Liu, Mark E. Schmidt, Richard Margolin et al. · Neurology · 2015 · 149 citations · Full text

Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092

Yi Yu, Ronald E. Savage, Sudharshan Eathiraj et al. · PLoS ONE · 2015 · 120 citations · Full text

Chemoprevention Strategy, Immunology, Cancer Biology +18

Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor

Jean‐Marc Lapierre, Sudharshan Eathiraj, David Vensel et al. · Journal of Medicinal Chemistry · 2016 · 105 citations · Full text

Pharmaceutical Science, Pharmacotherapy, Pharmaceutical Chemistry +18

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours

Kyriakos P. Papadopoulos, Bassell F. El-Rayes, Anthony W. Tolcher et al. · British Journal of Cancer · 2017 · 93 citations · Full text